IT1255222B - Fosforotidati di oligonucleotidi ciclici - Google Patents

Fosforotidati di oligonucleotidi ciclici

Info

Publication number
IT1255222B
IT1255222B ITMI921720A ITMI921720A IT1255222B IT 1255222 B IT1255222 B IT 1255222B IT MI921720 A ITMI921720 A IT MI921720A IT MI921720 A ITMI921720 A IT MI921720A IT 1255222 B IT1255222 B IT 1255222B
Authority
IT
Italy
Prior art keywords
group
independently
hydroxyl
hydrogen
compounds
Prior art date
Application number
ITMI921720A
Other languages
English (en)
Original Assignee
Erba Carlo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erba Carlo Spa filed Critical Erba Carlo Spa
Publication of ITMI921720A0 publication Critical patent/ITMI921720A0/it
Publication of ITMI921720A1 publication Critical patent/ITMI921720A1/it
Application granted granted Critical
Publication of IT1255222B publication Critical patent/IT1255222B/it

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Sono descritti composti di formula (I) (FORMULA I) in cui ogni gruppo B è, indipendentemente, una base eterociclica naturalmente presente o modificata legata attraverso un azoto o un atomo di carbonio dell'anello alla parte dello zucchero; ogni gruppo X è, indipendentemente, un idrogeno, un fluoro, un idrossile o un gruppo alcossilico da C a C6; ogni gruppo Y è, indipendentemente un idrogeno, un solfidrile o un idrossile, e i suoi sali farmaceuticamente accettabili. Un procedimento per la loro preparazione e la preparazione di composizioni farmaceutiche che li comprendono sono anche descritti. I composti di questa invenzione possono essere utili come antivirali, in particolare come agenti anti-HIV (Virus di Immunodeficienza Umana), vale a dire come farmaci da usare contro l'AIDS (Sindrome di Immunodeficienza Acquisita) terapeuticamente e/o profilatticamente.
ITMI921720A 1991-07-18 1992-07-15 Fosforotidati di oligonucleotidi ciclici IT1255222B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9115586A GB2257704B (en) 1991-07-18 1991-07-18 Cyclic oligonucleotides phosphorothioates

Publications (3)

Publication Number Publication Date
ITMI921720A0 ITMI921720A0 (it) 1992-07-15
ITMI921720A1 ITMI921720A1 (it) 1994-01-15
IT1255222B true IT1255222B (it) 1995-10-20

Family

ID=10698606

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI921720A IT1255222B (it) 1991-07-18 1992-07-15 Fosforotidati di oligonucleotidi ciclici

Country Status (5)

Country Link
US (1) US5547941A (it)
JP (1) JPH05186495A (it)
DE (1) DE4223438A1 (it)
GB (1) GB2257704B (it)
IT (1) IT1255222B (it)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620796B1 (en) * 1999-11-08 2003-09-16 Micrologix Biotech Inc. Combinatorial library synthesis and pharmaceutically active compounds produced thereby
KR20020069627A (ko) * 2001-02-27 2002-09-05 동부한농화학 주식회사 육환의 아자슈거를 가진 뉴클레오타이드 유도체를 포함한포스포로티오에이트 올리고뉴클레오타이드 및 이들의에이즈 치료제로서의 새로운 용도
WO2002092006A2 (en) * 2001-05-16 2002-11-21 Micrologix Biotech, Inc. Nucleic acid-based compounds and methods of use thereof
US7345163B2 (en) * 2002-08-28 2008-03-18 Quiatech Ab Process for separating and deprotecting oligonucleotides
AU2004275696B2 (en) 2003-07-28 2010-02-18 Karagen Pharmaceuticals, Inc. Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
US20070149451A1 (en) * 2003-11-17 2007-06-28 Holmes David G Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
WO2005089777A1 (en) * 2004-03-15 2005-09-29 Karaolis David K R A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
EP1782826A1 (en) * 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
WO2009133560A1 (en) * 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
CN102199183B (zh) * 2010-03-26 2013-12-18 北京大学 环二鸟苷酸及其类似物和制备方法
EP2858722B8 (en) 2012-06-08 2018-02-21 Aduro BioTech, Inc. Compostions and methods for cancer immunotherapy
US9695212B2 (en) 2012-12-13 2017-07-04 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
WO2014109256A1 (ja) * 2013-01-09 2014-07-17 国立大学法人東北大学 トリアゾール連結型環状ジヌクレオチド類縁体
US9840533B2 (en) 2013-04-29 2017-12-12 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
CR20160564A (es) 2014-06-04 2017-01-20 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos como moduladores de sting
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
EA035817B1 (ru) 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
CN107849084B (zh) 2015-12-03 2021-09-14 葛兰素史密斯克莱知识产权发展有限公司 作为sting调节剂的环状嘌呤二核苷酸
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
IL264049B2 (en) 2016-07-06 2023-11-01 Sperovie Biosciences Inc Compounds, preparations and methods for treating the disease
US10266558B2 (en) * 2016-10-07 2019-04-23 Alexandre Vasilievich Ivachtchenko Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
PE20210255A1 (es) 2016-12-01 2021-02-10 Takeda Pharmaceuticals Co Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon)
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
US11584774B2 (en) 2017-09-11 2023-02-21 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
US11707531B2 (en) 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
KR20200098511A (ko) 2017-11-10 2020-08-20 다케다 야쿠힌 고교 가부시키가이샤 Sting 조절제 화합물, 및 제조 및 사용 방법
BR112020024605A2 (pt) 2018-06-01 2021-04-06 Eisai R&D Management Co., Ltd. Métodos para o tratamento de câncer de bexiga
WO2020014127A1 (en) 2018-07-10 2020-01-16 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
US11691990B2 (en) 2018-08-16 2023-07-04 Eisai R&D Management Co., Ltd Salts of compounds and crystals thereof
WO2020227421A1 (en) 2019-05-09 2020-11-12 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
TWI901793B (zh) * 2020-10-20 2025-10-21 大陸商泰勵生物科技(上海)有限公司 多功能環二核苷酸及其用途
CN115160392B (zh) * 2020-10-20 2026-01-30 泰励生物科技(上海)有限公司 多功能环二核苷酸及其用途
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates

Also Published As

Publication number Publication date
GB9115586D0 (en) 1991-09-04
DE4223438A1 (de) 1993-01-21
JPH05186495A (ja) 1993-07-27
US5547941A (en) 1996-08-20
ITMI921720A0 (it) 1992-07-15
ITMI921720A1 (it) 1994-01-15
GB2257704B (en) 1995-03-01
GB2257704A (en) 1993-01-20

Similar Documents

Publication Publication Date Title
IT1255222B (it) Fosforotidati di oligonucleotidi ciclici
HUP0101999A2 (hu) 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
YU72602A (sh) Hidrofilni molekularni disperzioni rastvori karvedilola
ATE218580T1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
HUP9801336A2 (hu) 6-Szubsztituált-pirazolo[3,4-d]-pirimidin-4-on-származékok és az ezeket tartalmazó gyógyszerkészítmények
NO20052739L (no) CCR5-antagonister som medikamenter
HUT47217A (en) Process for producing pharmaceutical compositions containing indol derivatives as active components
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
AU5669398A (en) Novel cyclosporin derivatives, method of preparation and pharmaceutical compositions containing them
HUP0302474A2 (hu) Terápiásan hatásos tropánszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
MXPA03005464A (es) Agentes antivirales.
HUP0103063A2 (hu) Új 2H-piridazin-származékok, alkalmazásuk, ilyen hatóanyagot tartalmazó gyógyászati készítmények, és eljárás a hatóanyag előállítására
FR2762843B1 (fr) Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
AU5895496A (en) Phenyldihydrobenzofurans
AP1849A (en) Dosage regimen and pharmaceutical composition for emergency contraception
DE60205455D1 (de) Naphthyridinderivate
HUP9700005A2 (hu) 2-Ureido-benzamid-származékok és ilyeneket hatóanyagként tartalmazó gyógyszerkészítmények
DK0828727T3 (da) Cyclohexyldihydrobenzofuraner
SE0102055D0 (sv) New Compounds
SE0102440D0 (sv) New compound
TNSN90021A1 (fr) Procede de preparation de tetrahydroimidazo (1,4) benzodiazepin -2- thiones antivirales
HUP0100083A2 (hu) Piridingyűrűt tartalmazó kondenzált, tetraciklusos vegyületek, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények, valamint intermedierek
HU9303000D0 (en) Aryl-morpholine-derivatives and pharmaceutical compositions containing it and process for production thereof
HUP0000344A2 (hu) Lamivudint és zidovudint tartalmazó gyógyszerkészítmények
HUP9901659A2 (hu) Flupirtin alkalmazása a hematopoetikus sejtrendszer károsodásával kapcsolatos megbetegedések megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19950628